The use of coupons and manufacturer buydowns is increasing as a way to offset what would otherwise be increasing costs borne by the patients, according to Murray Aitken, senior vice president and executive director of the IQVIA Institute for Human Data Science,
Also, Forbes re-evaluates Theranos Founder Elizabeth Holmes' net worth, the FDA has approved the first liquid biopsy for lung cancer and Strata Oncology closed a $12 million Series A financing to advance its tumor sequencing business.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
The all-stock transaction brings together companies with a combined enterprise value of upwards of $23 billion and current market capitalization of $17.6 billion.
Indeed, the growth rate is supposed to increase each year through 2020, the report says - thanks largely to drugs targeting cancer.
A new IMS report found that the 2015 late phase pipeline includes 2,320 novel products - and projects that more than 200 new drugs will be approved by 2020.
Biosimilars compete directly with branded biologics that are now going off patent - and in five years, they'll account for 20 percent of the global pharmaceutical market.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
It's clear that more biosimilars are close to completion and marketing than not; 12 are in preclinical development, whereas 23 are almost ready to be filed.
Study suggests the impact that digital health can have on chronic conditions.
Kaiser Permanente reached a deal on new contracts for workers and Health Diagnostic Laboratory, Inc. filed for bankruptcy.
Few of the folks who champion digital health would make a case for apps as the be all end all solution to prevent the kind of complications that send healthcare costs into orbit. But as a JAMA article highlights, the benefits of many of the apps aimed at chronic conditions, such as diabetes, have limits. […]
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
It will be an important eight months for IMS Health. You’ll see fresh research on mobile app use, new customer announcements, results from early pilot programs, and new products meant to help AppScript, which lets doctors rate and “prescribe” mobile apps for their patients, come of age. IMS is pushing AppScript hard at HIMSS 2015 […]
Need proof that orphan indication’s the way to go? The demand for specialty medications – and their premium pricing – is driving up the total American spend on medication, a new study says. A revenue darling for most budding biotechs, specialty drugs acccounted for $124.1 billion of medication dollars spent, out of a total of […]
The Affordable Care Act and innovative biotech trends are having an impact on medication costs and healthcare spend generally, according to a new report by the IMS Health Institute for Healthcare Informatics. The report details medication costs in 2013 and shifting healthcare cost trends. Here are 10 of the most interesting findings in the report. […]
The growth of mobile health apps for consumers documented in the report by IMS Institute of Healthcare Informatics also includes behavioral health apps. The research institute assembled a helpful breakdown of the more than 18,000 consumer facing mobile health apps. It identified 558 mental health apps. The report also provides an outlook on the future […]